Dexrazoxaan bij anthracycline-geïnduceerde cardiotoxiciteit en anthracycline-extravasatie.

Translated title of the contribution: Dexrazoxane in anthracycline induced cardiotoxicity and extravasation

Andrew K.L. Goey, Jan H.M. Schellens, Jos H. Beijnen, Alwin D.R. Huitema

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)


Cardiotoxicity and extravasation injuries are extremely serious complications of anthracycline use. Both complications are probably caused by oxidative stress. Dexrazoxane has been approved as a cardioprotective agent and as an antidote in extravasation of anthracyclines. Randomized clinical trials have shown that dexrazoxane is the only cardioprotective agent proven to be effective in the treatment of anthracycline-induced cardiotoxicity. In these clinical studies dexrazoxane decreased the incidence of cardiac events and heart failure. Possible adverse effects of dexrazoxane when administered as a cardioprotective agent are a decreased antitumor effect of anthracyclines and the onset of secondary malignancies in children. As an antidote in anthracycline extravasation, clinical studies showed dexrazoxane to be highly efficacious in preventing the need for surgical resection. Dexrazoxane can be considered as the treatment of first choice for this indication. Dexrazoxane is well tolerated in general. The most commonly reported side effects are leukopenia, thrombocytopenia and local reactions at the infusion site.

Translated title of the contributionDexrazoxane in anthracycline induced cardiotoxicity and extravasation
Original languageDutch
Pages (from-to)A1155
JournalNederlands Tijdschrift voor Geneeskunde
Issue number23
Publication statusPublished - 2010
Externally publishedYes


Dive into the research topics of 'Dexrazoxane in anthracycline induced cardiotoxicity and extravasation'. Together they form a unique fingerprint.

Cite this